N/A

Average User
Rating
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis

USD 9.85

+0.10 (+1.03)%

USD 3.66B

7.88K

USD 15.88(+61.17%)

N/A

Icon

EVO

Evotec SE ADR (USD)
COMMON STOCK | NSD
USD 9.85
0.10 1.025641

N/A

Average User
Rating
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis

USD 3.66B

N/A

USD 9.85

Evotec SE ADR Stock Forecast

USD 15.88
(+61.17%)

Based on the Evotec SE ADR stock forecasts from 4 analysts, the average analyst target price for Evotec SE ADR is USD 15.88 over the next 12 months. Evotec SE ADR’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Evotec SE ADR is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Evotec SE ADR’s stock price was USD 9.85. Evotec SE ADR’s stock price has changed by +2.39% over the past week, +21.76% over the past month and -51.95% over the last year.

No recent analyst target price found for Evotec SE ADR
No recent average analyst rating found for Evotec SE ADR

Company Overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases,...Read More

https://www.evotec.com

Essener Bogen 7, Hamburg, Germany, 22419

4,715

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

  • 0.96

  • USD 21.55

  • 0.95

  • USD 7.80

  • 26,624

  • USD 10.93

  • 26,479

  • USD 8.75

  • N/A

  • N/A

  • 1.57%

  • N/A

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Security Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Evotec SE ADR (Sector: Drug Manufacturers-Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD
PPD Inc 0.00 (0.00%) USD16.61B 47.04 21.58
VTRS
Viatris Inc +0.10 (+0.82%) USD14.42B 18.02 6.97
NBIX
Neurocrine Biosciences Inc -0.71 (-0.64%) USD10.41B 180.48 98.51
MYL
Mylan N.V 0.00 (0.00%) USD8.59B 30.73 11.86
APHA
Tilray, Inc 0.00 (0.00%) USD6.86B 60.60 454.68
MNTA
Momenta Pharmaceuticals, Inc 0.00 (0.00%) USD6.24B N/A N/A
ALKS
Alkermes Plc +0.05 (+0.17%) USD4.73B N/A -72.85
ITCI
Intracellular Th -0.10 (-0.21%) USD4.45B N/A -14.58
LNTH
Lantheus Holdings Inc +1.14 (+1.98%) USD3.86B 36.91 16.96
HCM
HUTCHMED DRC +0.73 (+4.05%) USD3.64B 17.69 -6.38

ETFs Containing EVO

Symbol Name Weight Mer Price(Change) Market Cap
EXV9:F
iShares (DE) I - iShares .. 19.40 % 0.46 % +0.26 (+1.22%) USD0.27B
EXV9:XETRA
iShares (DE) I - iShares .. 19.40 % 0.46 % +0.02 (+0.07%) USD0.15B
ODDS
Pacer BlueStar Digital En.. 8.09 % 0.60 % +0.40 (+2.17%) USD0.75M
BETS:XETRA
HANetf ICAV - Fischer Spo.. 6.59 % 0.00 % 0.00 (0.00%) USD1.39M
BJK
VanEck Gaming ETF 6.47 % 0.62 % +0.60 (+1.37%) USD0.10B
FEUI:XETRA
Fidelity Europe Quality I.. 5.86 % 0.35 % -0.01 (-0.26%) USD0.04B
FEUQ:F
Fideliy UCITS ICAV - Euro.. 5.86 % 0.35 % +0.03 (+0.49%) N/A
FEUI:F
Fideliy UCITS ICAV - Euro.. 5.86 % 0.35 % 0.00 (0.00%) N/A
FEUQ:XETRA
Fidelity Europe Quality I.. 5.86 % 0.35 % -0.01 (-0.20%) USD8.66M
IBET
iBET Sports Betting & Gam.. 4.63 % 0.79 % +0.20 (+1.96%) USD1.41M
BETZ
Roundhill Sports Betting .. 4.14 % 0.75 % +0.39 (+2.41%) USD0.13B
EWD
iShares MSCI Sweden ETF 3.92 % 0.54 % +0.84 (+2.40%) USD0.31B
OMXS:LSE
iShares OMX Stockholm Cap.. 3.38 % 0.10 % +5.88 (+1.06%) USD6.90B
BFTR
BlackRock Future Innovato.. 3.00 % 0.80 % +0.89 (+3.25%) USD7.39M
OM3X:XETRA
iShares OMX Stockholm Cap.. 2.77 % 0.10 % 0.00 (0.00%) USD6.60B
FCIQ:CA
Fidelity International Hi.. 2.22 % 0.45 % +0.14 (+0.42%) USD0.41B
ITEP:LSE
HAN-GINS Tech Megatrend E.. 1.30 % 0.59 % +11.25 (+1.39%) USD0.08B
ITEK:LSE
HAN-GINS Tech Megatrend E.. 1.25 % 0.59 % +0.13 (+1.28%) USD0.08B
IESZ:LSE
iShares Edge MSCI Europe .. 0.62 % 0.25 % 0.00 (0.00%) USD0.03B

Frequently Asked Questions About EVO Stock

Based on ratings from 4 analysts Evotec SE ADR's stock is Hold . Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, 1 sell and 1 hold ratings.

Unfortunately we do not have enough data on EVO's stock to indicate if its a good dividend stock.

Based on targets from 4 analysts, the average taret price for EVO is USD 15.88 over the next 12 months. The maximum analyst target price is USD 18.5 while the minimum anlayst target price is USD 12.

EVO stock's Price/Earning ratio is 508.00. Our analysis grades EVO stock's Price / Earning ratio at F. This means that EVO stock's Price/Earning ratio is above 98% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the NSD exchange. Based on this EVO may be a overvalued for its sector.

The last closing price of EVO's stock was USD 9.85.

The most recent market capitalization for EVO is USD 3.66B.

Based on targets from 4 analysts, the average taret price for EVO is projected at USD 15.88 over the next 12 months. This means that EVO's stock price may go up by +61.17% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...